The gene-editing technology CRISPR shows early promise as a therapeutic strategy for the aggressive and difficult-to-treat brain cancer known as primary glioblastoma, according to findings of a new study from Gladstone Institutes. UCSF Anesthesia and Perioperative Care resident Alex Perez, MD, PhD, performed much of the computational work for this groundbreaking research. Read more on the Gladstone website.